Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

• Main Authors: Paton, Nicholas I., Gurumurthy, Meera, Lu, Qingshu, Leek, Francesca, Kwan, Philip, Koh, Hiromi W. L., Molton, James, Mortera, Lalaine, Naval, Sullian, Abu Bakar, Zamzurina, Pang, Yong-Kek, Lum, Lionel, Lim, Tow Keang, Cross, Gail B., Lekurwale, Ganesh, Choi, Hyungwon, Au, Veonice, Connolly, John, Hibberd, Martin, Green, Justin A., Team, Pascolizumab TB Trial
• Format: Article
• Published: Oxford University Press 2024
• Subjects: QR Microbiology; R Medicine (General)
• Online Access: http://eprints.um.edu.my/46996/; https://doi.org/10.1093/infdis/jiae104
• Institution: Universiti Malaya

Background Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody) as adjunctive tuberculosis treatment.Methods Participants wit...